Home » Meetings » ACAAI 2019 » ACAAI 2019 In-Depth Asthma
In-Depth Focus From ACAAI 2019: Asthma
For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
Treatment with omalizumab may reduce exacerbations of asthma in patients in several different airway reversibility subgroups.
Patients who began biologic treatment for asthma tended to have more progressive worsening of disease in the previous 2 years
Benralizumab does not induce changes in weight or blood pressure when administered for up to 1 year in patients with severe asthma.
The addition of formoterol to mometasone furoate was well tolerated and provided significant improvement in lung function in children compared with mometasone furoate alone.
In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire.
Response to omalizumab was similar regardless of the number and type of sensitizing allergens in patients with allergic asthma.
Load More
Open
Next post in ACAAI 2019 In-Depth Asthma
Close
Close more info about Omalizumab Reduces Asthma Exacerbations Across Airway Reversibility Subgroups
Loading...
Close more info about Omalizumab Reduces Asthma Exacerbations Across Airway Reversibility Subgroups
Loading...